Ceritinib and Other Second Generation ALK Inhibitors for Acquired Resistance in ALK-Positive NSCLC [720p]

Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib... Author: cancergrace Added: 05/16/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts